Which Is Better, Allergy Shots or Drops? It Depends on You

For people with genuine needle aversion, drops are often the more realistic option simply because adherence is what determines success. A treatment that triggers anxiety or avoidance is unlikely to be completed, and immunotherapy only works durably across a three-to-five-year course. Sublingual drops are taken under the tongue at home with no injections, which removes the needle barrier entirely. Caregiver-preference surveys consistently show families favor sublingual dosing for needle-fearful children. That said, needle aversion alone is not the only factor — allergen profile, asthma control, and ability to dose daily still matter. An allergist can help weigh needle tolerance against the other considerations rather than treating it as the sole deciding factor.

Distance is a meaningful factor that often favors drops. Traditional allergy shots require regular trips to a clinic — weekly during the build-up phase and then on a maintenance schedule — each followed by a 30-minute observation period. For patients in rural areas or with limited transportation, that travel burden is a common reason courses are abandoned. Sublingual drops are dosed at home daily, which removes routine clinic travel from the equation, and telehealth follow-up can handle monitoring. The trade-off is that drops require daily self-discipline rather than appointment-driven accountability. If reliable daily dosing is realistic for you, geographic distance is a strong point in favor of the at-home sublingual route.

Polysensitization tends to favor allergy shots, with one caveat. Allergy shots can be formulated as customized multi-allergen vials covering grasses, trees, weeds, dust mites, animal dander, and mold matched to your profile. FDA-approved sublingual tablets each treat only a single allergen, which is impractical if you react to several. Compounded multi-allergen sublingual drops can address multiple allergens at once and are used off-label, so they offer a sublingual path for polysensitized patients, though they lack the standardized evidence base of approved tablets. The decision comes down to whether you prefer the broader, better-studied multi-allergen coverage of injections or the at-home convenience of multi-allergen drops despite their thinner evidence.

Severity and asthma control are important safety considerations. Uncontrolled or severe asthma is a contraindication for immunotherapy of either route and must be stabilized first. For patients with significant systemic-reaction risk factors, the lower systemic-reaction rate of sublingual drops can be an advantage, since drops cause predominantly local oral reactions. However, severity also intersects with evidence strength: for certain allergens like mold and tree pollen, injection therapy has a more robust evidence base. There is no blanket rule that one route is better for severe allergies. An allergist should assess your asthma status, reaction history, and specific allergens before recommending a route, and certain conditions such as eosinophilic esophagitis specifically contraindicate sublingual therapy.

Adherence may be the single most important factor, because no immunotherapy works if it is not completed. Real-world data (Kiel et al. 2013) show low completion rates for both routes, with shots reaching three years more often than drops, likely because scheduled clinic visits enforce attendance. If you know you tend to forget daily routines, the appointment structure of shots may help you finish. If clinic visits are the barrier — due to schedule, distance, or needle aversion — then daily at-home drops paired with telehealth check-ins may be more sustainable for you. The better choice is honestly the one you are most likely to stick with, so realistic self-assessment of your own habits is essential.